MTIP
MACK

Magee Thomson Investment Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Magee Thomson Investment Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,128
Closed -$99K – 156
2014
Q4 		$99K Buy
+1,128
New +$82.2K 0.02% 89

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Magee Thomson Investment Partners's MACK Position: Q1 2015 in Review

Magee Thomson Investment Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2015, closing a stake of 1,128 shares — an estimated $99K sold.

Magee Thomson Investment Partners first reported a position in MACK in Q4 2014 and held it in 1 quarter. The position peaked at $99K in Q4 2014. 152 funds tracked by Wall St. Rank hold MACK as of Q1 2015.

  • Magee Thomson Investment Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 1,128 Merrimack Pharmaceuticals, Inc. shares in Q1 2015, an estimated $99K.
  • Magee Thomson Investment Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Magee Thomson Investment Partners's Merrimack Pharmaceuticals, Inc. position peaked at $99K in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2015.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2015, filed 4 May 2015.